The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

An antioxidant dispersion contains an oil component having a polyunsaturated fatty acid content of less than 50% by mass, a water-soluble antioxidant, at least one kind of compound selected from the group consisting of a polyhydric alcohol compound having 5 or less carbon atoms and reduced starch syrup, an emulsifier, and water. The emulsifier preferably contain a compound having an HLB value of 4.0 or less. In addition, in the antioxidant dispersion, a content of the emulsifier is preferably 0.5% by mass to 20% by mass with respect to a total mass of the antioxidant dispersion.

The present invention refers to the use of a surface-treated calcium carbonate-comprising material and/or magnesium carbonate-comprising material as oxygen scavenger; wherein the surface treatment agent is selected from the group consisting of ascorbic acid and/or salts thereof, gallic acid and/or salts thereof, unsaturated fatty acids and/or salts thereof, elemental iron, iron (II)-salts and iron (ID-comprising oxides, iron (II, III)-comprising oxides and mixtures thereof; and wherein the total weight of the surface treatment agent on the total surface area of the at least one calcium carbonate-comprising material and/or magnesium carbonate-comprising material is from 0.01 to 40 mg/m.sup.2, based on the at least one calcium carbonate-comprising material and/or magnesium carbonate-comprising material.

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

A hydrolytic stabilizer mixture is disclosed. The mixture comprise i) at least one carbodiimide and ii) co-stabilizer selected from the group consisting of aluminum oxide and aluminum oxyhydroxide. The mixture is useful in imparting to polymeric systems improved resistance to hydrolysis.

Described are antioxidant macromolecules and methods of making and using same.

This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.